Mediators of Inflammation 4, 75-89 (1995) L-ARGININE is converted to the highly reactive and unstable nitric oxide (NO) and .-citrulline by an enzyme named nitric oxide synthase (NOS). NO decomposes into other nitrogen oxides such as nitrite (NO) (NO) nitrate (NO-) (Fig. 1) . The enzyme responsible fo NO production has been named nitric oxide synthas, (NON). Although evidence exists that NO is th, primary product released by NOS, it is possible tha NOS-containing cells produce a mixture of NO, NO:
In 1987, NO was found to explain both the biological activity of the elusive endothelium-derived relaxina factor [2] [3] [4] [5] and the t-arginine dependent tumouricida activity of activated murine macrophages. Th, products of this enzymatic pathway are t-citrullin, and the highly reactive and unstable nitric oxid, (NO), which decomposes (after complexing witl certain forms 'of iron, or non-enzymatically) int( other nitrogen oxides such as nitrite (NO) nitrate (NO-) (Fig. 1) . The enzyme responsible fo NO production has been named nitric oxide synthas, (NON) . Although evidence exists that NO is th, primary product released by NOS, it is possible tha NOS-containing cells produce a mixture of NO, NO:
NO, NO-, N203, nitrosamines, non-protei nitrosothiols and S-nitrosylated proteins.
Soon after its discovery, the new metabolic pathway was found to be t-arginine dependent.
5,9-1 NO is synthesized from the terminal guanidino nitrogen atom of this amino acid (and not I)-arginine), without loss of the guanidino carbon atom. Although it was initially believed that cNOS produced NO by a different process without nucleotide-derived cofactors, recent work now supports a general scheme. 12 NOS incorporates molecular oxygen both into NO and citrulline. Activated macrophages form NO from r.o-hydroxy-t-arginine, 12 confirming the proposal that this compound is an intermediate in the biosynthesis of NO. 2,14 t-Homoarginine can serve as a substrate for iNOS, but not for cNOS. 2'15 Recently, NOS has been purified and cloned 16, 22 from cerebellum, endothelium, rodent macrophages and human hepatocytes (reviewed by Nathan3). NOS has a close homology to cytochrome P450 reductase. 17 The biochemical and molecular biological reports on NOS result in a confusing synopsis with respect to a scale of variables: specific activity, K for t-arginine, relative dependence on Ca 2+ and co-factors, subcellular distribution or the gene regulating the expression of this enzyme. Until the cloning from additional cells and species and the use of antibody probes clarify the systematics of the various forms of NOS, the division into two subclasses (cNOS and iNOS) can be retained as the most useful one.
The murine iNOS macrophage enzyme displays approximately 50% sequence homology to the cNOS of neuronal origin. 19 Macrophage iNOS mRNA is strikingly inducible and it is absent in quiescent macrophages. Like neuronal NOS, macrophage NOS has recognition sites for FAD, FMN and NADPH and has a consensus calmodulin binding site. [18] [19] [20] [21] [22] Calmodulin binds tightly as a subunit to iNOS, which explains why iNOS is Ca 2+ independent, in contrast tO cNOS. 2 Macrophages from the cloned macrophage cell line RAW264.7 from Albeson leukaemia virus-induced BALB/c lymphocytic lymphoma are rather exceptional as they also express cNOS activity, which is Ca 2+ dependent and decreases after activation with IFNy or LPS, or with increasing passage number. '4 Many studies have shown that iNOS 95, 96 Analysis of diacylglycerol synthesis provided direct evidence that NO synthesis in macrophages involves the activation of an unusual phosphatidylcholinespecific phospholipase C. 97 However, tyrosine phosphorylation may also participate in the induction of NOS, as protein tyrosine kinase inhibitors (of the tyrophostin AG 126 family) protect mice against LPS-induced lethal toxicity, correlating with the ability of these agents to block LPS-induced NO production in macrophages. 98, 99 Macrophages from mice with a targeted disruption of the IFN regulatory factor 1-gene produced very little NO. 15 The elevated expression of iNOS mRNA after co-stimulation has been shown to be due to increased stability by some investigators, but due to a much higher rate of transcription of the NOS gene by others. 4, 16 Macrophages derived from mice fed with a diet rich in n-3 polyunsaturated fatty acids produce more NO 2-in response to IFN, compared with macrophages from the control group. 11 Bronchoalveolar macrophages from rats fed diets rich in n-3 fatty acids produce significantly more NO than macrophages isolated from n-6 polyunsaturated fatty acids fed animals: changes in n-6-derived prostanoids may account for these data. 12 However 
Regulation of iNOS activity
Once iNOS has been expressed in macrophages, its activity is regulated by several factors, including auto-inactivation, and availability of substrate and cofactors.
Auto-inactivation: NO may function as a negative feedback modulator of iNOS activity by interacting with the enzyme-bound haem of iNOS, which may represent a mechanism by which the NOS pathway in activated macrophages is turned off. 174 '175 None of 14 monoclonal antibodies raised against iNOS from rat macrophages neutralized iNOS activity, but some of them enhanced enzyme activity through stabilization of the enzyme. 176 Recently, a novel posttranslational and non-degradative inactivation of iNOS has been described. LPS, after inducing iNOS, caused macrophages to inactivate the enzyme about 3 days later, ivy The mechanism which remains to be identified is novel as it decreases neither the amount nor the apparent molecular mass of the enzyme.
Bioavailability ofL-arginine: Arginine plays a pivotal role in body protein biosynthesis, biosynthesis of other amino acids and in the urea cycle 1, 178 (Fig. 2) . Resting macrophages express arginase and the enzyme is up-regulated after immune activation. 9, 18 Arginase releases urea from L-arginine (Fig. 2) 22 Miscellaneous inhibitors of iNOS induction: Co-incubation of murine peritoneal macrophages with mast cell granules during LPS activation dose-dependently inhibited macrophage-mediated tumour cell lysis, and this was associated with a decreased NO production. 23 The inhibitory effect was not due to histamine or serotonin present in the mast cell granules. Cloricromene, a coumarin derivative, which has been found to increase the survival of rats injected with lethal doses of LPS, inhibited the induction but not the activity of the enzyme. 24 Therefore, these agents may have anti-inflammatory/immunosuppressive effects. Pharmacological agents inhibiting iNOS induction in activated macrophages also include the bisbenzylisoquinoline alkaloids, anti-inflammatory constituents of plants of the families Menispermaceae and Ranunculaceae, which have been used as folk remedies in Japan and China. 25 Alltrans-retinoic acid, a retinoid with growth-inhibiting and differentiation-inducing properties, inhibited TNF and NO production in peritoneal macrophages. 27, 28 Inhibitors of iNOS activity Substrate analogues: After the discovery of the inhibition of NO formation by NG-monomethyl-t arginine (L-NMMA), ,2,29 other t-arginine analogues, i.e., t-NG-nitroarginine (t-NNA), its methyl ester (t-NAME) and N-iminoethyl-t-ornithine (t-NIO), have been shown to inhibit NOS by competition with L-arginine (reviewed by Moncada et al. and Nathan3). Previous studies have established that iNOS and cNOS may vary in their susceptibility to inhibitory i-arginine analogues. 211 The structure of the N substituent appears to determine isoform selectivity. t-NNA appeared to be about 300 times less potent as an inhibitor of mouse macrophage iNOS when compared with bovine brain cNOS, 214 whereas t-NMMA is more potent than -NNA as inhibitor of macrophage iNOS. 21 The irreversible inactivation of iNOS by t-NMMA requires NADPH-dependent hydroxylation. 211'215 Conversely, -NNA was significantly more potent than L-NMMA as inhibitor of cNOS in vascular endothelial cells. This could be due to the significant metabolism of t-NMMA, but not t-NNA, to t-citrulline in the endothelial cell. tcitrulline is subsequently transformed to t-arginine. 26 This indicates that L-NMMA may serve as a supply of substrate, as well as an inhibitor of NOS under in vivo conditions, t-NIO is a potent irreversible inhibitor of both isoforms. 21 These t-arginine analogues are taken up by macrophages. This is mediated by both the cationic y+ transporter (t-NMMA, t-NIO) and a neutral amino acid transporter (-NNA, L-NAME).
217,219 t-Arginine transport by system y+ is reduced by I-NMMA and t-NIO, but not affected by t-NNA and L-NAME. 218 ,219 A neutral amino acid transporter (Fig. 2) , with low substrate specificity and insensitive to LPS, mediated the uptake of t-citrulline, t-NNA and t-NAME. '8 Hence, these arginine analogues appear to be not specific for NOS, and may interfere with transport or other aspects of t-arginine metabolism.
The effects of guanidines and uraemic compounds, endogenous NOS inhibitors which may accumulate in renal failure, = have been tested on NO production in macrophages. Aminoguanidine, a bifunctional molecule contairiing the guanido group of t-arginine linked to hydrazine, inhibits iNOS in pancreatic B cells, macrophages, and endothelium-denuded blood vessels of LPStreated rats and has little effect on cNOS0221-224 N,N'-diaminoguanidine, though being less potent than aminoguanidine as inhibitor of iNOS, appeared to be more selective without effect on cNOS. 119 The combined data thus suggest that iNOS activity can be induced to some extent in human macrophages. However, in contrast to the indoleamine-2,3-dioxygenase effector pathway, 9'192,242 the expression of iNOS in human macrophages requires rather specific conditions and limited quantities of NO appear to be generated via the t-arginine dependent effector pathway.
Conclusion
In the past few years it has become clear that NO 
